申请/专利权人：贵州大学

申请日：2018-08-24

公开（公告）日：2021-04-13

公开（公告）号：CN109134478B

主分类号：C07D487/20(20060101)

分类号：C07D487/20(20060101);A61P35/00(20060101)

优先权：

专利状态码：有效-授权

法律状态：2021.04.13#授权;2019.01.29#实质审查的生效;2019.01.04#公开

摘要：本发明公开了一种含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物，本发明以各种取代的3‑NCS氧化吲哚与3‑丙二腈缩合的3‑烯氧化吲哚，按摩尔比为1:1的比例在二氯甲烷溶剂中，室温下进行3+2环加成反应，获得含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值。本发明操作简单易行，原料合成便宜易得，可以在各种有机溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。且该骨架化合物对人白血病细胞K562生长具有抑制活性。

主权项：1.一种含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物，其特征在于：该化合物具有如通式Ⅰ所示的结构： 式中，R1为甲基、乙基或苄基；R2为甲基、H或卤素；R3为甲基、CH2CO2tBu或CH2CO2Et；R4为甲基、H或卤素。

全文数据：含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物及其制备方法及应用技术领域本发明涉及化学技术领域，尤其是一种含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物及其制备方法及应用。背景技术根据药物设计中药效团迁越原理,把具有生物活性基团拼接到具有活性分子骨架中，在有机化学和医药化学中是极其重要的研究领域。多官能团氧化吲哚广泛存在天然产物和合成药物分子中，其中，尤其3,3'-吡咯双螺环氧化吲哚因为具有广泛的生物活性，吸引了许多化学工作者及医药化学团队的广泛关注，例如，化合物I是具有抗细菌活性；化合物II具有抗真菌活性，化合物III具有抗肿瘤活性。根据药物设计中药效团迁越原理,鉴于3,3'-吡咯双螺环氧化吲哚骨架化合物具有潜在的生物活性。因此，在3,3'-吡咯双螺环氧化吲哚骨架上，增加药性官能团丙二腈以及吡咯环上增加官能团硫代酮，合成一系列新的潜在多活性官能团的氧化吲哚衍生物，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值如附图10所示。发明内容本发明的目的是：提供一种含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物及其制备方法与应用，它是一类重要的医药中间体类似物和药物分子类似物，对药物筛选和制药行业具有重要的应用价值，且其合成方法非常经济简便。本发明还发现该类化合物在制备防治肿瘤疾病药物中的应用。本发明是这样实现的：含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物，该化合物具有如下通式I的结构：式中，R1为甲基、乙基或苄基；R2为甲基、H或卤素；R3为甲基、CH2CO2tBu或CH2CO2Et；R4为甲基、H或卤素。将各种取代的3-NCS氧化吲哚与3-丙二腈缩合的3-烯氧化吲哚，按摩尔比为1:1的比例在二氯甲烷溶剂中，室温下进行3+2环加成反应，获得含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物。合成路线如下：反应机理如下：其中各种取代的3-丙二腈缩合的3-烯氧化吲哚1以及3-NCS氧化吲哚2的结构式，其取代基满足R1为甲基、乙基或苄基；R2为甲基、H或卤素；R3为甲基、CH2CO2tBu或CH2CO2Et；R4为甲基、H或卤素。含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物在制备防治肿瘤疾病药物中的应用。通过采用上述技术方案，以各种取代的3-NCS氧化吲哚与3-丙二腈缩合的3-烯氧化吲哚，按摩尔比为1:1的比例在二氯甲烷溶剂中，室温下进行3+2环加成反应，获得含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值。且该化合物对人白血病细胞K562具有抑制活性的作用。本发明操作简单易行，原料合成便宜易得，可以在各种有机溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。此外，连续三季碳化合物的合成在有机化学合成领域是一个重要的挑战。附图说明附图1为本发明的实施例的化合物3aa单晶图；附图2为本发明的实施例的化合物3bb单晶图；附图3为本发明的实施例的化合物3cc单晶图；附图4为本发明的实施例的化合物3db单晶图；附图5为本发明的实施例的化合物3eb单晶图；附图6为本发明的实施例的化合物3ga单晶图；附图7为本发明的实施例的化合物3gb单晶图；附图8为本发明的实施例的化合物3ib单晶图；附图9为本发明的实施例的化合物3jc单晶图；附图10为本发明的设计思路。具体实施方式本发明的实施例：在反应管中依次加入154.5mg3-丙二腈缩合的3-烯氧化吲哚1a0.5mmol，102.0mg3-NCS氧化吲哚2a0.5mmol和5mL二氯甲烷，室温反应20min，TLC检测基本反应完全，过滤，二氯甲烷洗涤，纯化得化合物3aa，白色固体，熔点：112.2-113.6℃，20:1dr；产率:236.0mg92％。核磁共振和高分辨质谱测试等结果如下：1HNMRCD3COCD3,500MHzδ:1.37s,9H,3.10s,3H,4.33d,J＝17.5Hz,1H,4.50d,J＝17.5Hz,1H,6.88d,J＝8.0Hz,1H,7.00d,J＝8.0Hz,1H,7.08-7.11m,1H,7.24-7.27m,1H,7.37-7.40m,1H,7.45-7.49m,2H,7.84d,J＝7.5Hz,1H,10.77brs,1H.13CNMRCD3COCD3,100MHzδ:25.9,27.1,41.8,54.7,61.9,73.3,82.3,109.4,110.4,111.5,112.2,117.0,119.4,123.7,123.8,126.2,126.8,132.0,132.2,144.0,144.6,165.1,170.5,172.2,189.2.HRMSESI-TOFmz:Calcd.forC27H23N5NaO4S[M+Na]+:536.1363；Found:536.1364.化合物3ab至3ka的制备方法同化合物3aa，投料比与化合物3aa相同，可得到化合物3ab至3ka，反应产率和非对映选择性见表1-3，但需强调的是本发明的化合物不限于表1-3所表示的内容。表1为一种含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物的化学结构表2为一种含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物的化学结构表3为一种含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物的化学结构本实施例制备化合物3ab：白色固体；熔点：160.3-161.7℃；产率：234.6mg89％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:0.99-1.01m,3H,1.34s,9H,3.53-3.60m,1H,3.72-3.78m,1H,4.41-4.51m,2H,7.02d,J＝7.5Hz,1H,7.06-7.12m,2H,7.26-7.29m,1H,7.36d,J＝7.5Hz,1H,7.39-7.42m,1H,7.48-7.51m,1H,7.73d,J＝7.5Hz,1H,12.34brs,1H.13CNMRDMSO-d6,125MHzδ:12.6,27.8,35.3,42.2,55.2,61.6,73.6,82.6,110.3,111.2,111.9,112.5,116.7,119.6,124.1,124.3,126.4,127.1,132.4,132.8,143.6,144.0,165.7,170.7,171.9,188.2.HRMSESI-TOFmz:Calcd.forC28H25N5NaO4S[M+Na]+:550.1519；Found:550.1515.本实施例制备化合物3ba：白色固体；熔点：132.1-134.0℃；产率：225.6mg93％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRCD3COCD3,500MHzδ:1.11-1.14m,3H,3.10s,3H,4.04-4.13m,2H,4.46d,J＝17.5Hz,1H,4.56d,J＝17.5Hz,1H,6.89d,J＝8.0Hz,1H,7.01d,J＝8.0Hz,1H,7.08-7.11m,1H,7.25-7.28m,1H,7.38-7.41m,1H,7.45-7.49m,2H,7.84d,J＝8.0Hz,1H,10.77brs,1H.13CNMRCD3COCD3,125MHzδ:13.4,25.9,41.2,54.7,61.4,62.0,73.3,109.4,110.3,111.5,112.1,117.1,119.4,123.7,123.9,126.3,126.8,132.1,132.2,143.9,144.6,166.1,170.6,172.3,189.2.HRMSESI-TOFmz:Calcd.forC25H19N5NaO4S[M+Na]+:508.1050；Found:508.1054.本实施例制备化合物3bb：白色固体；熔点：155.4-156.9℃；产率：219.6mg88％；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:0.95-0.98m,3H,1.07-1.10m,3H,3.50-3.57m,1H,3.68-3.76m,1H,3.99-4.07m,2H,4.50-4.58m,2H,6.98d,J＝8.0Hz,1H,7.03-7.09m,2H,7.23-7.27m,1H,7.33d,J＝8.0Hz,1H,7.35-7.39m,1H,7.44-7.47m,1H,7.70d,J＝8.0Hz,1H,12.31brs,1H.13CNMRDMSO-d6,125MHzδ:12.2,13.8,34.9,41.2,54.7,61.2,61.3,73.1,109.9,110.7,111.4,112.0,116.3,119.1,123.7,124.0,126.0,126.6,132.1,132.3,143.1,143.3,166.3,170.2,171.4,187.7.HRMSESI-TOFmz:Calcd.forC26H21N5NaO4S[M+Na]+:522.1206；Found:522.1208.本实施例制备化合物3ca：白色固体；熔点：163.7-164.9℃；产率：250.4mg95％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRCD3COCD3,500MHzδ:1.37s,9H,2.36s,3H,3.11s,3H,4.28d,J＝17.5Hz,1H,4.46d,J＝17.5Hz,1H,6.87d,J＝8.0Hz,2H,7.07-7.10m,1H,7.28d,J＝8.0Hz,1H,7.37-7.40m,1H,7.46d,J＝8.0Hz,1H,7.67s,1H,10.74brs,1H.13CNMRCD3COCD3,125MHzδ:20.4,25.9,27.2,41.9,54.6,62.1,73.4,82.2,109.4,110.1,111.6,112.3,117.1,119.5,123.7,126.7,126.8,132.2,132.3,133.5,141.7,144.6,165.2,170.5,172.3,189.3.HRMSESI-TOFmz:Calcd.forC28H25N5NaO4S[M+Na]+:550.1519；Found:550.1524.本实施例制备化合物3cb：白色固体；熔点：178.3-179.7℃；产率：246.2mg91％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:0.95-0.97m,3H,1.30s,9H,2.29s,3H,3.50-3.54m,1H,3.73-3.77m,1H,4.33-4.44m,2H,6.92d,J＝8.5Hz,1H,6.99d,J＝8.0Hz,1H,7.04-7.07m,1H,7.27d,J＝8.0Hz,1H,7.32d,J＝7.5Hz,1H,7.35-7.38m,1H,7.49s,1H,12.27brs,1H.13CNMRDMSO-d6,125MHzδ:12.1,20.8,27.4,35.8,41.8,54.6,60.8,72.9,82.1,109.8,110.6,111.5,112.0,116.3,119.2,123.7,126.3,126.6,132.2,132.3,132.8,141.2,143.1,162.3,165.3,170.1,171.5,187.8.HRMSESI-TOFmz:Calcd.forC29H27N5NaO4S[M+Na]+:564.1676；Found:564.1681.本实施例制备化合物3cc：白色固体；熔点：168.3-169.9℃；产率：257.1mg95％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRCD3COCD3,500MHzδ:1.39s,9H,2.28s,3H,2.35s,3H,3.09s,3H,4.35d,J＝17.5Hz,1H,4.45d,J＝17.5Hz,1H,6.76d,J＝8.0Hz,1H,6.87d,J＝8.0Hz,1H,7.18d,J＝7.5Hz,1H,7.28s,2H,7.66s,1H,10.69brs,1H.13CNMRCD3COCD3,125MHzδ:19.8,25.4,26.6,41.4,54.2,61.6,72.8,81.7,108.6,109.5,111.0,111.8,116.6,118.9,126.2,127.1,131.7,131.8,132.9,133.0,141.1,141.6,164.7,170.0,171.6,188.7.HRMSESI-TOFmz:Calcd.forC29H27N5NaO4S[M+Na]+:564.1676；Found:564.1671.本实施例制备化合物3da：白色固体；熔点：168.7-170.2℃；产率：239.0mg90％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRCD3COCD3,500MHzδ:1.41s,9H,3.19s,3H,4.42d,J＝17.5Hz,1H,4.56d,J＝17.5Hz,1H,6.98d,J＝8.0Hz,1H,7.11-7.13m,1H,7.16d,J＝7.5Hz,1H,7.33-7.37m,1H,7.45-7.48m,1H,7.51d,J＝8.0Hz,1H,7.64-7.67m,1H,10.83brs,1H.13CNMRCD3COCD3,125MHzδ:26.0,27.1,41.9,54.5,61.4,73.2,82.4,109.6,111.4,111.8,111.9d,JCF＝23.8Hz,113.9d,JCF＝27.5Hz,118.5,118.6,118.7,119.2,123.9,126.9,132.4,140.4,144.6,159.2d,JCF＝238.8Hz,165.0,170.3,172.1,188.7.HRMSESI-TOFmz:Calcd.forC27H22FN5NaO4S[M+Na]+:554.1269；Found:554.1264.本实施例制备化合物3bd：白色固体；熔点：158.9-160.3℃；产率：253.5mg93％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.09-1.12m,3H,3.05s,3H,3.98-4.09m,2H,4.58-4.66m,2H,6.98-7.01m,1H,7.04-7.07m,2H,7.24-7.30m,2H,7.46-7.50m,1H,7.64-7.66m,1H,12.38brs,1H.13CNMRDMSO-d6,125MHzδ:14.3,27.1,41.7,55.3,61.8,73.5,105.4,111.5,111.6,112.4,115.0d,JCF＝238.8Hz,116.6,119.1d,JCF＝23.8Hz,120.9,121.0,124.6,126.1,132.8,140.7,143.7,159.2d,JCF＝27.5Hz,166.8,170.5,172.2,188.0.HRMSESI-TOFmz:Calcd.forC25H18FN5NaO4S[M+Na]+:526.0956；Found:526.0958.本实施例制备化合物3dc：白色固体；熔点：135.1-136.9℃；产率：242.6mg89％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.32s,9H,2.23s,3H,3.05s,3H,4.42-4.51m,2H,6.86d,J＝8.0Hz,1H,7.09-7.13m,2H,7.20d,J＝8.0Hz,1H,7.38-7.43m,2H,12.35brs,1H.13CNMRDMSO-d6,125MHzδ:20.6,26.5,27.4,27.5,41.9,54.8,61.1,73.4,82.3,109.8,111.3,111.9,112.3,113.1d,JCF＝26.3Hz,117.9,118.0,118.8,118.9d,JCF＝23.8Hz,127.1,132.5,133.3,140.0,141.5,158.5d,JCF＝238.8Hz,165.2,170.0,171.6,187.3.HRMSESI-TOFmz:Calcd.forC28H24FN5NaO4S[M+Na]+:568.1425；Found:568.1429.本实施例制备化合物3dd：白色固体；熔点：182.3-184.1℃；产率：241.6mg88％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.33s,9H,3.09s,3H,4.48-4.56m,2H,7.02-7.07m,2H,7.13-7.15m,1H,7.28-7.32m,1H,7.38-7.45m,2H,12.42brs,1H.13CNMRDMSO-d6,125MHzδ:26.8,27.4,27.5,41.9,54.9,61.0,73.1,82.4,111.1,111.4,111.8,112.5,112.6,113.2d,JCF＝26.3Hz,114.8d,JCF＝26.3Hz,117.6,117.7,118.9d,JCF＝23.8Hz,119.2d,JCF＝22.5Hz,120.3,120.4,139.9,140.2,158.6d,JCF＝240.1Hz,158.9d,JCF＝238.8Hz,165.1,169.9,171.7,187.2.HRMSESI-TOFmz:Calcd.forC27H21F2N5NaO4S[M+Na]+:572.1175；Found:572.1176.本实施例制备化合物3ea：白色固体；熔点：133.5-135.1℃；产率：259.8mg95％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.30s,9H,3.07s,3H,4.40-4.49m,2H,6.97d,J＝8.0Hz,1H,7.07-7.12m,2H,7.30d,J＝7.5Hz,1H,7.38-7.41m,1H,7.58-7.61m,2H,12.40brs,1H.13CNMRDMSO-d6,125MHzδ:26.5,27.4,41.9,54.5,60.9,73.5,82.4,110.1,111.3,111.8,112.6,118.2,118.7,124.1,125.3,126.4,127.9,132.2,132.5,142.6,143.8,165.1,169.8,171.8,187.3.HRMSESI-TOFmz:Calcd.forC27H22ClN5NaO4S[M+Na]+:570.0973；Found:570.0977.本实施例制备化合物3eb：白色固体；熔点：159.3-161.1℃；产率：238.4mg85％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:0.98-1.01m,3H,1.30s,9H,3.49-3.53m,1H,3.79-3.83m,1H,4.41-4.50m,2H,7.02-713m,3H,7.31d,J＝7.5Hz,1H,7.32-7.41m,1H,7.60-7.64m,2H,12.37brs,1H.13CNMRDMSO-d6,125MHzδ:12.2,27.5,34.9,41.9,54.5,60.7,73.1,82.4,110.1,111.3,111.8,112.7,118.1,118.9,124.0,125.8,126.6,127.8,132.1,132.5,142.6,143.0,165.1,169.8,171.4,187.3.HRMSESI-TOFmz:Calcd.forC28H24ClN5NaO4S[M+Na]+:584.1130；Found:584.1135.本实施例制备化合物3ec：白色固体；熔点：163.1-164.3℃；产率：263.7mg94％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.09s,9H,1.99s,3H,2.81s,3H,4.18-4.28m,2H,6.62d,J＝8.0Hz,1H,6.86d,J＝8.8Hz,2H,6.95d,J＝7.6Hz,1H,7.35d,J＝8.4Hz,2H,12.13brs,1H.13CNMRDMSO-d6,125MHzδ:21.1,26.9,27.9,42.3,55.1,61.4,73.9,82.8,110.2,111.6,112.3,112.9,118.7,119.2,125.8,127.5,128.3,132.5,132.9,133.7,141.8,142.9,165.5,170.2,172.1,187.6.HRMSESI-TOFmz:Calcd.forC28H24ClN5NaO4S[M+Na]+:584.1130；Found:584.1135.本实施例制备化合物3ed：白色固体；熔点：137.8-138.4℃；产率：262.8mg93％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.33s,9H,3.09s,3H,4.49-4.56m,2H,7.02-7.05m,2H,7.13d,J＝8.0Hz,1H,7.28-7.32m,1H,7.61-7.63m,2H,12.45brs,1H.13CNMRDMSO-d6,125MHzδ:27.1,27.8,27.9,42.3,55.2,61.3,73.6,82.9,111.5,111.8,111.9,112.2,113.2,115.1d,JCF＝27.5Hz,118.4,119.3d,JCF＝23.8Hz,120.7,120.8,125.9,128.5,132.8,140.5,142.9,159.3d,JCF＝240.3Hz,165.5,170.1,172.2,187.6.HRMSESI-TOFmz:Calcd.forC27H21ClFN5NaO4S[M+Na]+:588.0879；Found:588.0874.本实施例制备化合物3fa：白色固体；熔点：168.9-170.0℃；产率：232.0mg93％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRCD3COCD3,500MHzδ:1.15-1.18m,3H,2.40s,3H,3.16s,3H,4.08-4.16m,2H,4.45d,J＝17.5Hz,1H,4.57d,J＝17.5Hz,1H,6.92d,J＝7.5Hz,2H,7.12-7.15m,1H,7.31d,J＝8.5Hz,1H,7.41-7.44m,1H,7.48d,J＝8.0Hz,1H,7.71s,1H,10.80brs,1H.13CNMRCD3COCD3,125MHzδ:13.4,20.3,25.9,41.2,54.7,61.3,61.9,73.3,109.4,110.0,111.5,112.2,117.1,119.4,123.7,126.7,126.8,132.2,132.3,133.6,141.5,144.6,166.1,170.5,172.3,189.3.HRMSESI-TOFmz:Calcd.forC26H21N5NaO4S[M+Na]+:522.1206；Found:522.1211.本实施例制备化合物3fb：白色固体；熔点：151.1-153.2℃；产率：225.7mg88％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:0.95-0.98m,3H,1.07-1.09m,3H,2.29s,3H,3.49-3.56m,1H,3.72-3.79m,1H,3.97-4.08m,2H,4.46-4.54m,2H,6.92d,J＝8.5Hz,1H,6.98d,J＝8.0Hz,1H,7.05-7.08m,1H,7.26d,J＝8.5Hz,1H,7.32d,J＝7.5Hz,1H,7.35-7.38m,2H,7.49s,1H,12.28brs,1H.13CNMRDMSO-d6,125MHzδ:12.1,13.8,20.8,34.8,41.2,45.7,54.9,61.3,73.3,109.8,110.4,111.5,112.1,116.4,119.4,123.6,126.4,126.6,132.2,132.3,132.9,141.0,143.1,166.3,170.2,171.6,187.5.HRMSESI-TOFmz:Calcd.forC27H23N5NaO4S[M+Na]+:536.1363；Found:536.1361.本实施例制备化合物3fc：白色固体；熔点：170.3-171.9℃；产率：230.9mg90％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.09-1.12m,3H,2.22s,3H,2.30s,3H,3.03s,3H,3.97-4.10m,2H,4.49-4.57m,2H,6.82d,8.0Hz,1H,6.93d,J＝8.5Hz,1H,7.11s,1H,7.17d,J＝8.0Hz,1H,7.26d,J＝8.0Hz,1H,7.45s,1H,12.28brs,1H.13CNMRDMSO-d6,125MHzδ:13.9,20.6,20.8,26.4,41.2,54.7,61.3,73.4,109.5,110.4,111.4,112.1,116.5,119.0,127.0,132.2,133.1,133.2,141.0,141.5,166.3,170.1,171.8,187.7.HRMSESI-TOFmz:Calcd.forC27H23N5NaO4S[M+Na]+:536.1363；Found:536.1366.本实施例制备化合物3fd：白色固体；熔点：153.1-154.8℃；产率：232.6mg90％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.09-1.12m,3H,2.31s,3H,3.06s,3H,3.98-4.08m,2H,4.53-4.62m,2H,6.95d,J＝8.0Hz,1H,6.98-7.01m,1H,7.03-7.06m,1H,7.25-7.30m,2H,7.45s,1H,12.36brs,1H.13CNMRDMSO-d6,125MHzδ:14.3,21.2,27.1,41.7,55.3,61.8,73.5,111.0,111.6,111.7,112.4,115.0d,JCF＝26.3Hz,116.7,119.0d,JCF＝23.8Hz,126.4,133.0,133.9,140.6,141.3,159.1d,JCF＝240.5Hz,166.8,170.4,172.3,188.0.HRMSESI-TOFmz:Calcd.forC26H20FN5NaO4S[M+Na]+:540.1112；Found:540.1112.本实施例制备化合物3ga：白色固体；熔点：163.3-165.1℃；产率：218.8mg87％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.06-1.09m,3H,3.08s,3H,3.98-4.06m,2H,4.53-4.60m,2H,6.98d,J＝8.0Hz,1H,7.08-7.15m,2H,7.32d,J＝8.0Hz,1H,7.39-7.42m,3H,12.40brs,1H.13CNMRDMSO-d6,125MHzδ:13.8,26.5,41.4,54.6,60.8,61.4,73.4,110.1,111.2,111.8,112.3,113.2d,JCF＝27.5Hz,117.9,118.7,119.1d,JCF＝22.5Hz,124.0,126.5,132.4,139.8,143.9,158.5d,JCF＝240.0Hz,166.2,170.0,171.7,187.3.HRMSESI-TOFmz:Calcd.forC25H18FN5NaO4S[M+Na]+:526.0956；Found:526.0958.本实施例制备化合物3gb：白色固体；熔点：163.4-164.8℃；产率：245.6mg95％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:0.96-0.99m,3H,1.06-1.09m,3H,3.51-3.58m,1H,3.75-3.82m,1H,3.97-4.07m,2H,4.53-4.60m,2H,7.02d,J＝8.0Hz,1H,7.07-7.15m,2H,7.32d,J＝8.0Hz,1H,7.38-7.45m,3H,12.32brs,1H.13CNMRDMSO-d6,125MHzδ:12.2,13.8,34.9,41.3,54.6,60.9,61.4,73.2,110.0,111.3,111.7,112.3,113.6d,JCF＝27.5Hz,117.7,118.9,119.0,123.9,126.7,132.5,139.8,143.0,158.5d,JCF＝238.8Hz,166.2,170.0,171.4,187.3.HRMSESI-TOFmz:Calcd.forC26H20FN5NaO4S[M+Na]+:540.1112；Found:540.1115.本实施例制备化合物3gc：白色固体；熔点：150.3-151.8℃；产率：245.5mg95％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.10s,3H,2.23s,3H,3.06s,3H,3.98-4.09m,2H,4.55-4.63m,2H,6.86d,J＝8.0Hz,1H,7.12s,1H,7.13-7.15m,1H,7.38-7.41m,2H.13CNMRDMSO-d6,125MHzδ:13.9,20.6,26.5,41.3,54.7,61.0,61.4,73.4,109.8,111.2,111.9,112.3,113.1,113.3,117.9,118.0,118.7,118.9,119.1,127.1,132.5,133.3,139.8,141.5,157.5,159.4,166.2,170.0,171.6,187.3.HRMSESI-TOFmz:Calcd.forC26H20FN5NaO4S[M+Na]+:540.1112；Found:540.1112.本实施例制备化合物3gd：白色固体；熔点：170.3-171.1℃；产率：226.6mg87％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.09-1.12m,3H,3.09s,3H,3.96-4.01m,1H,4.04-4.10m,1H,4.59-4.67m,2H,7.01-7.07m,2H,7.14-7.16m,1H,7.29-7.33m,1H,7.38-7.45m,2H,12.44brs,1H.13CNMRDMSO-d6,125MHzδ:14.3,27.2,41.8,55.3,61.5,61.9,73.6,111.5,111.8,112.2,112.9,113.0,113.7d,JCF＝26.3Hz,115.1d,JCF＝26.3Hz,118.1,119.3d,JCF＝22.5Hz,119.7d,JCF＝23.8Hz,120.7,120.8,140.2,140.6,159.0d,JCF＝240.0Hz,159.2d,JCF＝238.8Hz,166.7,170.3,172.1,187.6.HRMSESI-TOFmz:Calcd.forC25H17F2N5NaO4S[M+Na]+:544.0862；Found:544.0867.本实施例制备化合物3ha：白色固体；熔点：161.1-162.5℃；产率：230.8mg89％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.07-1.09m,3H,3.07s,3H,3.98-4.06m,2H,4.53-4.60m,2H,6.98d,J＝8.0Hz,1H,7.08-7.13m,2H,7.29d,J＝7.5Hz,1H,7.39-7.42m,1H,7.58-7.61m,2H,12.41brs,1H.13CNMRDMSO-d6,125MHzδ:13.9,26.5,41.4,54.5,60.9,61.4,73.5,110.1,111.2,111.7,112.5,118.3,118.7,124.1,125.4,126.4,128.0,132.3,132.5,142.4,143.8,166.1,169.8,171.8,187.3.HRMSESI-TOFmz:Calcd.forC25H18ClN5NaO4S[M+Na]+:542.0660；Found:542.0665.本实施例制备化合物3ib：白色固体；熔点：165.3-167.0℃；产率：245.1mg92％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:0.98-1.10m,3H,1.06-1.09m,3H,3.44-3.55m,1H,3.78-3.85m,1H,3.98-4.07m,2H,4.58s,2H,7.03d,J＝8.0Hz,1H,7.07-7.11m,1H,7.13d,J＝8.5Hz,1H,7.31d,J＝7.5Hz,1H,7.39-7.42m,1H,7.60d,J＝8.5Hz,1H,7.64s,1H,12.39brs,1H.13CNMRDMSO-d6,125MHzδ:12.2,13.8,35.0,41.3,54.5,60.7,61.4,73.1,110.1,111.3,111.7,112.7,118.1,118.8,124.0,125.9,126.6,127.9,132.2,132.6,142.4,143.0,166.1,169.8,171.4,187.3.HRMSESI-TOFmz:Calcd.forC26H20ClN5NaO4S[M+Na]+:556.0817；Found:556.0817.本实施例制备化合物3ie：白色固体；熔点：132.0-133.8℃；产率：267.6mg90％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.04-1.07m,3H,3.96-4.06m,2H,4.61s,2H,4.75d,J＝16.0Hz,1H,5.03d,J＝16.0Hz,1H,6.79d,J＝8.0Hz,1H,7.01-7.03m,2H,7.06-7.09m,1H,7.17d,J＝8.0Hz,1H,7.24-7.26m,3H,7.30-7.36m,2H,7.64d,J＝8.0Hz,1H,7.68-7.69m,1H,12.48brs,1H.13CNMRDMSO-d6,125MHzδ:8.7,13.8,41.4,43.3,45.8,61.4,110.8,112.6,126.1,126.8,127.7,128.3,128.7,134.5,142.5,143.3,166.2,170.0,172.0.HRMSESI-TOFmz:Calcd.forC31H22ClN5NaO4S[M+Na]+:618.0973；Found:618.0977.本实施例制备化合物3ic：白色固体；熔点：191.3-192.5℃；产率：247.8mg93％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.09-1.12m,3H,2.23s,3H,3.05s,3H,3.98-4.08m,2H,4.56-4.64m,2H,6.86d,J＝8.0Hz,1H,7.10s,1H,7.13d,J＝8.5Hz,1H,7.19-7.21m,1H,7.58-7.61m,2H,12.37brs,1H.13CNMRDMSO-d6,125MHzδ:13.9,20.6,26.5,41.3,54.6,60.9,61.4,73.4,109.8,111.2,111.8,112.6,118.3,118.6,125.4,127.0,128.0,132.5,133.4,141.4,142.4,166.1,169.8,171.6,187.3.HRMSESI-TOFmz:Calcd.forC26H20ClN5NaO4S[M+Na]+:556.0817；Found:556.0819.本实施例制备化合物3bc：白色固体；熔点：151.7-153.2℃；产率：217.1mg87％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:1.09-1.12m,3H,2.23s,3H,3.01s,3H,3.99-4.09m,2H,4.52-4.61m,2H,6.81d,J＝8.0Hz,1H,7.05d,J＝8.0Hz,1H,7.11s,1H,7.18d,J＝8.0Hz,1H,7.22-7.25m,1H,7.44-7.47m,1H,7.65d,J＝7.5Hz,1H,12.30brs,1H.13CNMRDMSO-d6,125MHzδ:13.9,20.6,26.5,41.2,54.8,61.3,73.3,109.5,110.7,111.4,112.1,116.5,119.0,124.0,125.6,127.0,132.1,132.3,133.1,141.6,143.3,166.3,170.3,171.7,187.6.HRMSESI-TOFmz:Calcd.forC26H21N5NaO4S[M+Na]+:522.1206；Found:522.1207.本实施例制备化合物3db：白色固体；熔点：167.3-169.5℃；产率：221.4mg88％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:0.99-1.02m,3H,1.34s,9H,3.54-3.61m,1H,3.78-3.85m,1H,4.44-4.53m,2H,7.06d,J＝8.0Hz,1H,7.10-7.17m,2H,7.36d,J＝7.5Hz,1H,7.42-7.48m,2H,12.42brs,1H.13CNMRDMSO-d6,125MHzδ:12.2,27.4,34.9,41.9,54.4,60.7,73.1,82.3,110.1,111.3,111.8,112.5,113.5d,JCF＝27.5Hz,117.7,119.0,123.9,126.7,132.5,140.0,143.0,158.4d,JCF＝238.8Hz,165.2,170.0,171.4,187.3.HRMSESI-TOFmz:Calcd.forC28H24FN5NaO4S[M+Na]+:568.1425；Found:568.1429.本实施例制备化合物3jc：白色固体；熔点：163.3-165.1℃；产率：230.2mg95％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,500MHzδ:2.23s,3H,3.02s,3H,3.56s,3H,4.59s,2H,6.82d,J＝8.0Hz,1H,7.05d,J＝8.0Hz,1H,7.11s,1H,7.16-7.19m,1H,7.23-7.26m,1H,7.44-7.47m,1H,7.65d,J＝8.0Hz,1H,10.77brs,1H.13CNMRDMSO-d6,125MHzδ:20.6,26.5,41.1,52.3,54.8,61.3,73.4,109.6,110.7,111.4,112.1,116.4,118.9,124.0,125.6,127.1,132.2,132.3,133.1,141.6,143.3,166.9,170.2,171.7,187.7.HRMSESI-TOFmz:Calcd.forC25H19N5NaO4S[M+Na]+:508.1050；Found:508.1054.本实施例制备化合物3ka：白色固体；熔点：138.1-139.5℃；产率：183.8mg89％,20:1dr；核磁共振和高分辨质谱测试等结果如下：1HNMRDMSO-d6,400MHzδ:3.00s,3H,3.03s,3H,6.89-6.91m,1H,7.02d,J＝8.0Hz,1H,7.06-7.10m,1H,7.18-7.22m,1H,7.33-7.37m,2H,7.42-7.46m,1H,7.60d,J＝7.6Hz,1H,12.31brs,1H.13CNMRDMSO-d6,100MHzδ:26.9,27.0,55.1,62.1,73.9,110.4,110.8,111.9,113.0,117.1,119.6,124.1,124.4,125.9,126.6,132.8,132.9,144.5,144.6,170.5,172.4,188.4.HRMSESI-TOFmz:Calcd.forC22H15N5NaO2S[M+Na]+:436.0839；Found:436.0845.本发明的式1化合物具有重要的生物活性，体外对人白血病细胞K562的细胞毒性试验表明：此类式1所示的结构含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物对肿瘤细胞生长具有抑制作用，有可能发展成为新的防治肿瘤药物。但需强调的是本发明的化合物不限于人白血病细胞K562表示的细胞毒性。药理实施例：化合物3dc,3gd,3ha,3ec和3ka对K562细胞的细胞毒性K562人慢性髓系白血病细胞用RPMI-1640培养基培养，培养基中含10％的胎牛血清，100UmL的青霉素和100UmL链霉素。细胞以每孔5000个细胞的浓度加入到96孔中，在37℃含5％CO2潮湿空气的培养箱中培养24小时。细胞存活率的测定用改良MTT法。细胞经过24小时的孵育后，分别将新配的化合物3dc,3gd,3ha,3ec和3ka的二甲基亚砜溶液以浓度梯度加入到各孔中，使孔中化合物最终浓度分别为5μmolL,10μmolL,20μmolL,40μmolL和80μmolL。48小时后，每孔加入10μLMTT5mgmL的磷酸盐缓冲液，再继续在37℃培养4小时后，离心5分钟除去未转化的MTT，每孔中加入150μL二甲基亚砜。以溶解还原的MTT晶体甲臜formazan，用酶标仪在490nm波长测定OD值。其中化合物3dc,3gd,3ha,3ec和3ka对K562细胞半抑制浓度IC50由spss软件19版本分析得到。化合物3dc对K562肿瘤细胞的IC50为34.7μmolL；化合物3gd对K562肿瘤细胞的IC50为57.6μmolL；化合物3ha对K562肿瘤细胞的IC50为43.7μmolL；化合物3ec对K562肿瘤细胞的IC50为57.1.8μmolL；化合物3ka对K562肿瘤细胞的IC50为69.0μmolL；而阳性对照顺铂对K562肿瘤细胞的IC50为27.8μmolL。实验结论：K562细胞是测试化合物对肿瘤细胞的细胞毒性的有效工具和评价指标。本实验表明此类式1所示的含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物对K562细胞具有较强的细胞毒性，有可能发展成新的具有抗肿瘤作用的药物。从以上药理实施例中我们可以看出这些化合物对人白血病细胞K562显示有一定的细胞毒性。可见这些化合物具有开发成为抗肿瘤药物的潜力，值得继续深入研究下去。

权利要求：1.一种含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物，其特征在于：该化合物具有如通式Ⅰ所示的结构：式中，R1为甲基、乙基或苄基；R2为甲基、H或卤素；R3为甲基、CH2CO2tBu或CH2CO2Et；R4为甲基、H或卤素。2.一种如权利要求1所述的含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物的制备方法，其特征在于：将各种取代的3-NCS氧化吲哚与3-丙二腈缩合的3-烯氧化吲哚，按摩尔比为1:1的比例在二氯甲烷溶剂中，室温下进行3+2环加成反应，获得含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物；合成路线如下：反应机理如下：其中各种取代的3-丙二腈缩合的3-烯氧化吲哚1以及3-NCS氧化吲哚2的结构式，其取代基满足R1为甲基、乙基或苄基；R2为甲基、H或卤素；R3为甲基、CH2CO2tBu或CH2CO2Et；R4为甲基、H或卤素。3.一种如权利要求1所述的含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物在制备防治肿瘤疾病药物中的应用。

百度查询： 贵州大学 含连续三季碳的硫代吡咯酮拼接双螺环氧化吲哚化合物及其制备方法及应用

免责声明
1、本报告根据公开、合法渠道获得相关数据和信息，力求客观、公正，但并不保证数据的最终完整性和准确性。
2、报告中的分析和结论仅反映本公司于发布本报告当日的职业理解，仅供参考使用，不能作为本公司承担任何法律责任的依据或者凭证。

阅读全文 双屏查看 官方信息 专利公告 收藏专利 下载PDF 下载WORD